813 related articles for article (PubMed ID: 23958540)
1. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
[TBL] [Abstract][Full Text] [Related]
2. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
Eutamene H; Bradesi S; Larauche M; Theodorou V; Beaufrand C; Ohning G; Fioramonti J; Cohen M; Bryant AP; Kurtz C; Currie MG; Mayer EA; Bueno L
Neurogastroenterol Motil; 2010 Mar; 22(3):312-e84. PubMed ID: 19706070
[TBL] [Abstract][Full Text] [Related]
3. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
[TBL] [Abstract][Full Text] [Related]
4. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
[TBL] [Abstract][Full Text] [Related]
5. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
[TBL] [Abstract][Full Text] [Related]
6. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.
Silos-Santiago I; Hannig G; Eutamene H; Ustinova EE; Bernier SG; Ge P; Graul C; Jacobson S; Jin H; Liong E; Kessler MM; Reza T; Rivers S; Shea C; Tchernychev B; Bryant AP; Kurtz CB; Bueno L; Pezzone MA; Currie MG
Pain; 2013 Sep; 154(9):1820-1830. PubMed ID: 23748116
[TBL] [Abstract][Full Text] [Related]
8. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
[TBL] [Abstract][Full Text] [Related]
10. Challenges of managing pain in constipation-predominant IBS: clinical perspectives on antinociceptive actions of linaclotide.
Hasler WL; Owyang C
Gastroenterology; 2013 Dec; 145(6):1196-9. PubMed ID: 24409483
[No Abstract] [Full Text] [Related]
11. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
[TBL] [Abstract][Full Text] [Related]
12. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
[TBL] [Abstract][Full Text] [Related]
13. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
14. Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.
Grundy L; Harrington AM; Castro J; Garcia-Caraballo S; Deiteren A; Maddern J; Rychkov GY; Ge P; Peters S; Feil R; Miller P; Ghetti A; Hannig G; Kurtz CB; Silos-Santiago I; Brierley SM
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282832
[TBL] [Abstract][Full Text] [Related]
15. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
[TBL] [Abstract][Full Text] [Related]
17. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Videlock EJ; Cheng V; Cremonini F
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
Sedky AA; Magdy Y
Life Sci; 2020 Sep; 256():117960. PubMed ID: 32534033
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological and clinical profile of linaclotide (Linzess
Keto Y; Kosako M
Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
